ArticleJournal of controlled release : official journal of the Controlled Release Society2010
Enhanced in vivo bioluminescence imaging using liposomal luciferin delivery system.
Article in Journal of controlled release : official journal of the Controlled Release Society, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 50 citations in OpenAlex.
- Encapsulation of doxorubicin in magnesium acetate liposomes as a pH-sensitive drug carrier for tumor therapy.iScience · 2025Article
- Bioluminescent Systems for Theranostic Applications.International journal of molecular sciences · 2024Review
- Article
- Strategies for improving the intratumoral distribution of liposomal drugs in cancer therapy.Expert opinion on drug delivery · 2016Review
- Development of a cell-based bioassay for phospholipase A2-triggered liposomal drug release.PloS one · 2015Article
- Opening up the optical imaging window using nano-luciferin.Pharmaceutical research · 2014Article
- Bioluminescence: a versatile technique for imaging cellular and molecular features.MedChemComm · 2014Article
- A physiological perspective on the use of imaging to assess the in vivo delivery of therapeutics.Annals of biomedical engineering · 2014Review
- Complete regression of local cancer using temperature-sensitive liposomes combined with ultrasound-mediated hyperthermia.Journal of controlled release : official journal of the Controlled Release Society · 2013Article
- A phantom for visualization of three-dimensional drug release by ultrasound-induced mild hyperthermia.Medical physics · 2013Article
- Targeting of liposomes via PSGL1 for enhanced tumor accumulation.Pharmaceutical research · 2013Article
- Phase-shift, stimuli-responsive drug carriers for targeted delivery.Therapeutic delivery · 2011Review
- Noninvasive biophotonic imaging for studies of infectious disease.FEMS microbiology reviews · 2011Review
- In vivo bioluminescent imaging (BLI): noninvasive visualization and interrogation of biological processes in living animals.Sensors (Basel, Switzerland) · 2011Review
- In vivo imaging of hydrogen peroxide production in a murine tumor model with a chemoselective bioluminescent reporter.Proceedings of the National Academy of Sciences of the United States of America · 2010Article
- Copper-doxorubicin as a nanoparticle cargo retains efficacy with minimal toxicity.Molecular pharmaceutics · 2010Article
- Noninvasive thermometry assisted by a dual-function ultrasound transducer for mild hyperthermia.IEEE transactions on ultrasonics, ferroelectrics, and frequency control · 2010Article
- Article
- Phase-shift, stimuli-responsive perfluorocarbon nanodroplets for drug delivery to cancer.Wiley interdisciplinary reviews. Nanomedicine and nanobiotechnologyReview
Corrections and comments
- Commented on by
Authors and funding
8 authors at 2 institutions in 1 country.
Funding
Abstract
To provide a continuous and prolonged delivery of the substrate D-luciferin for bioluminescence imaging in vivo, luciferin was encapsulated into liposomes using either the pH gradient or acetate gradient method. Under optimum loading conditions, 0.17 mg luciferin was loaded per mg of lipid with 90-95% encapsulation efficiency, where active loading was 6 to 18-fold higher than that obtained with passive loading. Liposomal luciferin in a long-circulating formulation had good shelf stability, with 10% release over 3-month storage at 4 degrees C. Pharmacokinetic profiles of free and liposomal luciferin were then evaluated in transgenic mice expressing luciferase. In contrast to rapid in vivo clearance of free luciferin (t(1/2)=3.54 min), luciferin encapsulated into long-circulating liposomes showed a prolonged release over 24h. The first-order release rate constant of luciferin from long-circulating liposomes, as estimated from the best fit of the analytical model to the experimental data, was 0.01 h(-1). Insonation of luciferin-loaded temperature-sensitive liposomes directly injected into one tumor of Met1-luc tumor-bearing mice resulted in immediate emission of light. Systemic injection of luciferin-loaded long-circulating liposomes into Met1-luc tumor-bearing mice, followed by unilateral ultrasound-induced hyperthermia, produced a gradual increase in radiance over time, reaching a peak at 4-7 h post-ultrasound.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.